Media headlines about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive on Thursday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a news impact score of 0.24 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.8435674354404 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several research firms have recently weighed in on OSUR. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, December 30th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. OraSure Technologies presently has a consensus rating of “Buy” and a consensus target price of $22.25.
Shares of NASDAQ:OSUR traded up $0.10 during mid-day trading on Thursday, hitting $16.89. The company’s stock had a trading volume of 1,031,739 shares, compared to its average volume of 666,098. The stock has a market capitalization of $1,027.29, a price-to-earnings ratio of 33.12, a P/E/G ratio of 4.99 and a beta of 1.60. OraSure Technologies has a one year low of $12.02 and a one year high of $23.01.
In related news, EVP Brian Smith sold 20,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares of the company’s stock, valued at $504,507.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stephen S. Phd Tang sold 23,333 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “OraSure Technologies (NASDAQ:OSUR) Receiving Somewhat Favorable News Coverage, Report Shows” was published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://baseballnewssource.com/2018/03/29/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-orasure-technologies-osur-share-price/1971158.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.